![]() |
![]() |
||||||||||||||||||||||||||||||||||||||
![]() |
|
ProCertus has identified three products for initial clinical testing. DermX and ProDermaCel share a common active agent and are both applied to squamous skin using the same delivery vehicle. They are being tested for safety and efficacy in concurrent Phase I/II clinical studies in cancer patients. OralX has been formulated for topical application to oral mucosa and will be tested in separate safety and efficacy studies. |
|||||||||||||||||||||||||||||||||||||